Tharimmune, Inc. (NASDAQ:THAR) CEO Randy Milby has recently increased his stake in the company by purchasing additional shares. According to a recent SEC filing, Milby acquired 4,600 shares of Tharimmune common stock on December 19 at a price of $2.12 per share. This transaction represents a total investment of $9,752. The purchase comes as the stock trades near its 52-week low of $1.83, having declined about 73% over the past year. Following this purchase, Milby now holds 17,534 shares directly in the company. This move underscores Milby’s continued confidence in Tharimmune’s prospects as it advances its pharmaceutical preparations. According to InvestingPro analysis, while the company maintains a healthy current ratio of 2.35, indicating strong short-term liquidity, its overall financial health score remains weak. The stock currently appears slightly undervalued based on InvestingPro’s Fair Value analysis, with 8 additional key insights available to subscribers.
In other recent news, Tharimmune, Inc. has initiated a Phase 2 study for TH104, a potential treatment for pruritus in primary biliary cholangitis patients. The firm has received positive feedback from the FDA and EMA and anticipates the commencement of the trial in 2025. Furthermore, Tharimmune has secured $2.02 million in private funding led by Gravitas Capital and SDS Capital Group. Unfortunately, the company also cancelled a potential merger with Intract Pharma Ltd.
Tharimmune has been issued a Buy rating by Rodman & Renshaw, contingent on the successful development and commercial launch of TH104. The company has also appointed Sanam Parikh to its Board of Directors, enhancing its leadership team.
In addition, Tharimmune is set to receive a European patent for its biodegradable polymeric nanoparticles technology, expected to enhance cancer therapies. The company has also entered into an exclusive licensing agreement with Intract Pharma for an innovative oral delivery platform for anti-inflammatory treatments. These are the latest developments in Tharimmune’s ongoing efforts to expand its product pipeline and clinical development programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.